Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Glial α-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo.

Olsen AL, Feany MB.

Glia. 2019 Jul 3. doi: 10.1002/glia.23671. [Epub ahead of print]

PMID:
31267577
2.

PARP Inhibitors and Parkinson's Disease.

Olsen AL, Feany MB.

N Engl J Med. 2019 Jan 31;380(5):492-494. doi: 10.1056/NEJMcibr1814680. No abstract available.

PMID:
30699325
3.

Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics.

Bardai FH, Ordonez DG, Bailey RM, Hamm M, Lewis J, Feany MB.

PLoS Biol. 2018 Dec 20;16(12):e2006265. doi: 10.1371/journal.pbio.2006265. eCollection 2018 Dec.

4.

Tissue and cellular rigidity and mechanosensitive signaling activation in Alexander disease.

Wang L, Xia J, Li J, Hagemann TL, Jones JR, Fraenkel E, Weitz DA, Zhang SC, Messing A, Feany MB.

Nat Commun. 2018 May 15;9(1):1899. doi: 10.1038/s41467-018-04269-7.

5.

α-synuclein Induces Mitochondrial Dysfunction through Spectrin and the Actin Cytoskeleton.

Ordonez DG, Lee MK, Feany MB.

Neuron. 2018 Jan 3;97(1):108-124.e6. doi: 10.1016/j.neuron.2017.11.036. Epub 2017 Dec 14.

6.

A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations In Vivo.

Bardai FH, Wang L, Mutreja Y, Yenjerla M, Gamblin TC, Feany MB.

J Neurosci. 2018 Jan 3;38(1):108-119. doi: 10.1523/JNEUROSCI.1550-17.2017. Epub 2017 Nov 14.

7.

Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.

Collier TJ, Srivastava KR, Justman C, Grammatopoulous T, Hutter-Paier B, Prokesch M, Havas D, Rochet JC, Liu F, Jock K, de Oliveira P, Stirtz GL, Dettmer U, Sortwell CE, Feany MB, Lansbury P, Lapidus L, Paumier KL.

Neurobiol Dis. 2017 Oct;106:191-204. doi: 10.1016/j.nbd.2017.07.007. Epub 2017 Jul 12.

8.

Defective Phagocytic Corpse Processing Results in Neurodegeneration and Can Be Rescued by TORC1 Activation.

Etchegaray JI, Elguero EJ, Tran JA, Sinatra V, Feany MB, McCall K.

J Neurosci. 2016 Mar 16;36(11):3170-83. doi: 10.1523/JNEUROSCI.1912-15.2016.

9.

An In Vivo Pharmacological Screen Identifies Cholinergic Signaling as a Therapeutic Target in Glial-Based Nervous System Disease.

Wang L, Hagemann TL, Messing A, Feany MB.

J Neurosci. 2016 Feb 3;36(5):1445-55. doi: 10.1523/JNEUROSCI.0256-15.2016.

10.

Lamin Dysfunction Mediates Neurodegeneration in Tauopathies.

Frost B, Bardai FH, Feany MB.

Curr Biol. 2016 Jan 11;26(1):129-36. doi: 10.1016/j.cub.2015.11.039. Epub 2015 Dec 24.

11.

Nitric oxide mediates glial-induced neurodegeneration in Alexander disease.

Wang L, Hagemann TL, Kalwa H, Michel T, Messing A, Feany MB.

Nat Commun. 2015 Nov 26;6:8966. doi: 10.1038/ncomms9966.

12.

Connecting the dots between tau dysfunction and neurodegeneration.

Frost B, Götz J, Feany MB.

Trends Cell Biol. 2015 Jan;25(1):46-53. doi: 10.1016/j.tcb.2014.07.005. Epub 2014 Aug 26. Review.

13.

Glia are critical for the neuropathology of complex I deficiency in Drosophila.

Hegde VR, Vogel R, Feany MB.

Hum Mol Genet. 2014 Sep 1;23(17):4686-92. doi: 10.1093/hmg/ddu188. Epub 2014 Apr 23.

14.

Tau promotes neurodegeneration through global chromatin relaxation.

Frost B, Hemberg M, Lewis J, Feany MB.

Nat Neurosci. 2014 Mar;17(3):357-66. doi: 10.1038/nn.3639. Epub 2014 Jan 26.

15.

Functional screening in Drosophila identifies Alzheimer's disease susceptibility genes and implicates Tau-mediated mechanisms.

Shulman JM, Imboywa S, Giagtzoglou N, Powers MP, Hu Y, Devenport D, Chipendo P, Chibnik LB, Diamond A, Perrimon N, Brown NH, De Jager PL, Feany MB.

Hum Mol Genet. 2014 Feb 15;23(4):870-7. doi: 10.1093/hmg/ddt478. Epub 2013 Sep 25.

16.

A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease.

Hill-Burns EM, Singh N, Ganguly P, Hamza TH, Montimurro J, Kay DM, Yearout D, Sheehan P, Frodey K, McLear JA, Feany MB, Hanes SD, Wolfgang WJ, Zabetian CP, Factor SA, Payami H.

Pharmacogenomics J. 2013 Dec;13(6):530-7. doi: 10.1038/tpj.2012.38. Epub 2012 Oct 2.

17.

Tau promotes neurodegeneration via DRP1 mislocalization in vivo.

DuBoff B, Götz J, Feany MB.

Neuron. 2012 Aug 23;75(4):618-32. doi: 10.1016/j.neuron.2012.06.026.

18.

Mediators of a long-term movement abnormality in a Drosophila melanogaster model of classic galactosemia.

Ryan EL, DuBoff B, Feany MB, Fridovich-Keil JL.

Dis Model Mech. 2012 Nov;5(6):796-803. doi: 10.1242/dmm.009050. Epub 2012 Jun 26.

19.

Alexander disease.

Messing A, Brenner M, Feany MB, Nedergaard M, Goldman JE.

J Neurosci. 2012 Apr 11;32(15):5017-23. doi: 10.1523/JNEUROSCI.5384-11.2012. No abstract available.

20.

A neuroprotective role for the DNA damage checkpoint in tauopathy.

Khurana V, Merlo P, DuBoff B, Fulga TA, Sharp KA, Campbell SD, Götz J, Feany MB.

Aging Cell. 2012 Apr;11(2):360-2. doi: 10.1111/j.1474-9726.2011.00778.x. Epub 2012 Feb 1.

21.

Protein misfolding and oxidative stress promote glial-mediated neurodegeneration in an Alexander disease model.

Wang L, Colodner KJ, Feany MB.

J Neurosci. 2011 Feb 23;31(8):2868-77. doi: 10.1523/JNEUROSCI.3410-10.2011.

22.

Functional screening of Alzheimer pathology genome-wide association signals in Drosophila.

Shulman JM, Chipendo P, Chibnik LB, Aubin C, Tran D, Keenan BT, Kramer PL, Schneider JA, Bennett DA, Feany MB, De Jager PL.

Am J Hum Genet. 2011 Feb 11;88(2):232-8. doi: 10.1016/j.ajhg.2011.01.006. Epub 2011 Feb 3.

23.

Glial fibrillary tangles and JAK/STAT-mediated glial and neuronal cell death in a Drosophila model of glial tauopathy.

Colodner KJ, Feany MB.

J Neurosci. 2010 Dec 1;30(48):16102-13. doi: 10.1523/JNEUROSCI.2491-10.2010.

24.

Parkinson's disease: genetics and pathogenesis.

Shulman JM, De Jager PL, Feany MB.

Annu Rev Pathol. 2011;6:193-222. doi: 10.1146/annurev-pathol-011110-130242. Review.

PMID:
21034221
25.

The unfolded protein response protects from tau neurotoxicity in vivo.

Loewen CA, Feany MB.

PLoS One. 2010 Sep 29;5(9). pii: e13084. doi: 10.1371/journal.pone.0013084.

26.

Parkinson's disease: insights from non-traditional model organisms.

Pienaar IS, Götz J, Feany MB.

Prog Neurobiol. 2010 Dec;92(4):558-71. doi: 10.1016/j.pneurobio.2010.09.001. Epub 2010 Sep 21. Review.

PMID:
20851733
27.

Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo.

Khurana V, Elson-Schwab I, Fulga TA, Sharp KA, Loewen CA, Mulkearns E, Tyynelä J, Scherzer CR, Feany MB.

PLoS Genet. 2010 Jul 15;6(7):e1001026. doi: 10.1371/journal.pgen.1001026.

28.

ASIP Outstanding Investigator Award Lecture. New approaches to the pathology and genetics of neurodegeneration.

Feany MB.

Am J Pathol. 2010 May;176(5):2058-66. doi: 10.2353/ajpath.2010.091077. Epub 2010 Apr 2.

29.

Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation.

Chen L, Periquet M, Wang X, Negro A, McLean PJ, Hyman BT, Feany MB.

J Clin Invest. 2009 Nov;119(11):3257-65. doi: 10.1172/JCI39088. Epub 2009 Oct 12.

30.

Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease.

McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ.

J Neuropathol Exp Neurol. 2009 May;68(5):515-24. doi: 10.1097/NEN.0b013e3181a24b53.

31.

Inactivation of Drosophila Huntingtin affects long-term adult functioning and the pathogenesis of a Huntington's disease model.

Zhang S, Feany MB, Saraswati S, Littleton JT, Perrimon N.

Dis Model Mech. 2009 May-Jun;2(5-6):247-66. doi: 10.1242/dmm.000653. Epub 2009 Apr 6.

32.

Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo.

Cullen V, Lindfors M, Ng J, Paetau A, Swinton E, Kolodziej P, Boston H, Saftig P, Woulfe J, Feany MB, Myllykangas L, Schlossmacher MG, Tyynelä J.

Mol Brain. 2009 Feb 9;2:5. doi: 10.1186/1756-6606-2-5.

33.

Progressive aggregation despite chaperone associations of a mutant SOD1-YFP in transgenic mice that develop ALS.

Wang J, Farr GW, Zeiss CJ, Rodriguez-Gil DJ, Wilson JH, Furtak K, Rutkowski DT, Kaufman RJ, Ruse CI, Yates JR 3rd, Perrin S, Feany MB, Horwich AL.

Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1392-7. doi: 10.1073/pnas.0813045106. Epub 2009 Jan 26.

34.

In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons.

Spires-Jones TL, de Calignon A, Matsui T, Zehr C, Pitstick R, Wu HY, Osetek JD, Jones PB, Bacskai BJ, Feany MB, Carlson GA, Ashe KH, Lewis J, Hyman BT.

J Neurosci. 2008 Jan 23;28(4):862-7. doi: 10.1523/JNEUROSCI.3072-08.2008.

35.

Tau phosphorylation sites work in concert to promote neurotoxicity in vivo.

Steinhilb ML, Dias-Santagata D, Fulga TA, Felch DL, Feany MB.

Mol Biol Cell. 2007 Dec;18(12):5060-8. Epub 2007 Oct 10.

36.

Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.

Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG.

Science. 2007 Jul 27;317(5837):516-9. Epub 2007 Jun 21.

37.

Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.

Dufty BM, Warner LR, Hou ST, Jiang SX, Gomez-Isla T, Leenhouts KM, Oxford JT, Feany MB, Masliah E, Rohn TT.

Am J Pathol. 2007 May;170(5):1725-38.

38.

Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo.

Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB.

J Neurosci. 2007 Mar 21;27(12):3338-46.

39.

S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila.

Steinhilb ML, Dias-Santagata D, Mulkearns EE, Shulman JM, Biernat J, Mandelkow EM, Feany MB.

J Neurosci Res. 2007 May 1;85(6):1271-8.

PMID:
17335084
40.

Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo.

Fulga TA, Elson-Schwab I, Khurana V, Steinhilb ML, Spires TL, Hyman BT, Feany MB.

Nat Cell Biol. 2007 Feb;9(2):139-48. Epub 2006 Dec 24.

PMID:
17187063
41.

Oxidative stress mediates tau-induced neurodegeneration in Drosophila.

Dias-Santagata D, Fulga TA, Duttaroy A, Feany MB.

J Clin Invest. 2007 Jan;117(1):236-45. Epub 2006 Dec 14.

42.

Connecting cell-cycle activation to neurodegeneration in Drosophila.

Khurana V, Feany MB.

Biochim Biophys Acta. 2007 Apr;1772(4):446-56. Epub 2006 Oct 18. Review.

43.

Accelerated accumulation of misfolded prion protein and spongiform degeneration in a Drosophila model of Gerstmann-Sträussler-Scheinker syndrome.

Gavin BA, Dolph MJ, Deleault NR, Geoghegan JC, Khurana V, Feany MB, Dolph PJ, Supattapone S.

J Neurosci. 2006 Nov 29;26(48):12408-14.

44.

Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity.

Kontopoulos E, Parvin JD, Feany MB.

Hum Mol Genet. 2006 Oct 15;15(20):3012-23. Epub 2006 Sep 7.

PMID:
16959795
45.

TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model.

Khurana V, Lu Y, Steinhilb ML, Oldham S, Shulman JM, Feany MB.

Curr Biol. 2006 Feb 7;16(3):230-41.

46.

Senseless makes sense for spinocerebellar ataxia-1.

Khurana V, Fulga TA, Feany MB.

Nat Neurosci. 2005 Nov;8(11):1422-4. No abstract available.

PMID:
16251977
47.

Cathepsin D-deficient Drosophila recapitulate the key features of neuronal ceroid lipofuscinoses.

Myllykangas L, Tyynelä J, Page-McCaw A, Rubin GM, Haltia MJ, Feany MB.

Neurobiol Dis. 2005 Jun-Jul;19(1-2):194-9.

PMID:
15837574
48.
49.

Proliferative potential of human astrocytes.

Colodner KJ, Montana RA, Anthony DC, Folkerth RD, De Girolami U, Feany MB.

J Neuropathol Exp Neurol. 2005 Feb;64(2):163-9.

PMID:
15751231
50.

New genetic insights into Parkinson's disease.

Feany MB.

N Engl J Med. 2004 Nov 4;351(19):1937-40. No abstract available.

PMID:
15525720

Supplemental Content

Loading ...
Support Center